THX Pharma
ALTHX.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | €0 | €0 | €0 | €0 |
| - Cash | €0 | €0 | €0 | €0 |
| + Debt | €0 | €0 | €0 | €0 |
| Enterprise Value | €0 | €0 | €0 | €0 |
| Revenue | €0 | €0 | €0 | €0 |
| % Growth | -100% | -98.4% | 2,864.1% | – |
| Gross Profit | -€0 | -€0 | €0 | -€0 |
| % Margin | – | -1,851.7% | 43.6% | -3,472.8% |
| EBITDA | -€0 | -€0 | -€0 | -€0 |
| % Margin | – | -3,355.8% | -8.1% | -4,875.7% |
| Net Income | -€0 | -€0 | €0 | -€0 |
| % Margin | – | -2,662.4% | 4.6% | -4,261.1% |
| EPS Diluted | -0.13 | -0.11 | 0.013 | -0.41 |
| % Growth | -18.2% | -946.2% | 103.2% | – |
| Operating Cash Flow | – | -€0 | -€0 | -€0 |
| Capital Expenditures | – | -€0 | -€0 | -€0 |
| Free Cash Flow | – | -€0 | -€0 | -€0 |